Premium
Follow‐Up of Anti‐IgA Antibodies in Primary Immunodeficient Patients Treated with γ‐Globulin
Author(s) -
Ferreira A.,
Rodriguez M.C. García,
Fontán G.
Publication year - 1989
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1989.tb02032.x
Subject(s) - antibody , immunology , medicine , globulin , iga deficiency , gamma globulin , immunoglobulin a , immunopathology , incidence (geometry) , adverse effect , immunoglobulin g , physics , optics
. The levels of anti‐IgA antibodies and the appearance of adverse reactions following γ‐globulin administration in 41 patients affected by primary antibody defects treated with intramuscular (IMGG) or intravenous γ‐globulin (IVGG), and 3 patients with the Wiskott‐Aldrich syndrome (WAS) have been studied during a 31‐month period. Anti‐IgA antibodies were restricted to patients with circulating B lymphocytes and measurable amounts of IgA. The incidence of anti‐IgA antibodies in the immunodeficient patients studied was 22.7%, and 2 of the 3 WAS patients also had high levels of anti‐IgA antibodies. The presence of moderate levels of anti‐IgA antibodies (up to 1/1,600) was not associated with adverse reactions. Our results indicate a significant relationship <0.02) between persistence of anti‐IgA antibodies and IMGG administration.